However, these inhibitors affect hundreds of targets resulting in poor selectivity and quick tumor-adaptative response in acute myeloid leukemia models and other cancer models, causing MYC levels to remain unchanged [19–21]. The gene discussed is MYC; the disease is neoplasm.